U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H12N4O6S
Molecular Weight 316.29
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISATORIBINE ANHYDROUS

SMILES

NC1=NC2=C(SC(=O)N2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C(=O)N1

InChI

InChIKey=TZYVRXZQAWPIAB-FCLHUMLKSA-N
InChI=1S/C10H12N4O6S/c11-9-12-6-5(7(18)13-9)21-10(19)14(6)8-4(17)3(16)2(1-15)20-8/h2-4,8,15-17H,1H2,(H3,11,12,13,18)/t2-,3-,4-,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C10H12N4O6S
Molecular Weight 316.29
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

ISATORIBINE, a guanosine analog, is an immunopotentiating agent. It is a selective agonist of toll‐like receptor 7, a pattern-recognition receptor that activates the innate immune response.

Approval Year

PubMed

PubMed

TitleDatePubMed
Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.
2006-08
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.
2005-09
Broad-spectrum activity of 8-chloro-7-deazaguanosine against RNA virus infections in mice and rats.
1995-03
Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections.
1994-10
Alkylpurines as immunopotentiating agents. Synthesis and antiviral activity of certain alkylguanines.
1993-10-29
Synthesis and antiviral activity of certain guanosine analogues in the thiazolo[4,5-d]pyrimidine ring system.
1991-10
Guanosine analogues. Synthesis of nucleosides of certain 3-substituted 6-aminopyrazolo[3,4-d]pyrimidin-4(5H)-ones as potential immunotherapeutic agents.
1990-08
Antiviral activity of the novel immune modulator 7-thia-8-oxoguanosine.
1990-02
Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice.
1990-02
Thiazolo[4,5-d]pyrimidine nucleosides. The synthesis of certain 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidines as potential immunotherapeutic agents.
1990-01
Broad-spectrum in vivo antiviral activity of 7-thia-8-oxoguanosine, a novel immunopotentiating agent.
1989-09
Patents

Patents

Substance Class Chemical
Created
by admin
on Mon Mar 31 18:38:04 GMT 2025
Edited
by admin
on Mon Mar 31 18:38:04 GMT 2025
Record UNII
2DNT962H92
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
5-AMINO-3-.BETA.-D-RIBOFURANOSYLTHIAZOLO(4,5-D)PYRIMIDINE-2,7(3H,6H)-DIONE
Preferred Name English
ISATORIBINE ANHYDROUS
Common Name English
isatoribine [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C308
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
Code System Code Type Description
INN
7843
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
PUBCHEM
135409474
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
NCI_THESAURUS
C90812
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
CAS
122970-40-5
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
SMS_ID
300000034322
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
FDA UNII
2DNT962H92
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
EPA CompTox
DTXSID20924330
Created by admin on Mon Mar 31 18:38:04 GMT 2025 , Edited by admin on Mon Mar 31 18:38:04 GMT 2025
PRIMARY
Related Record Type Details
SOLVATE->ANHYDROUS
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
PRODRUG -> METABOLITE ACTIVE
Class: Antiviral, Nucleoside; Mechanism of Action: Interferon alpha stimulant, Natural killer cell stimulant, Toll-like receptor 7 agonist; Highest Development Phases: Discontinued for Hepatitis B, Hepatitis C; Most Recent Events: 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in Europe (PO), 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in United Kingdom (PO), 26 Jul 2007 Discontinued - Preclinical for Hepatitis C treatment in USA (PO)
Related Record Type Details
ACTIVE MOIETY